Overview
Stimalia is a bioelectronic medicine company offering TraumaTone, described as the world's first percutaneous bioelectronic implant for PTSD. The device is designed to address treatment-resistant cases by modulating the body's alarm system through stellate ganglion targeting.
Key people
In the news
- One more stage on our autumn tour. 🎤 We left one out last time: on 24 November, Stimalia will pitch at the imec.istart Investor Day at the Wintercircus in Ghent. That makes five stages in one month for a single idea: calming the body’s stress circuit at its source, the stellate ganglion, with a tiny wireless implant.
- One platform. Two species. Four stages in one month. Stimalia is on the road this autumn: Brussels, San Francisco, Brussels again, then Bruges. We are building a miniaturized, battery-free injectable implant that modulates the stellate ganglion, a key relay of the fight-or-flight response. TraumaTone for treatment-resistant PTSD in humans. CalmTone Vet for canine anxiety in dogs. I will pitch at Brain Innovation Days and the HealthTech Investor Summit. Our Chief Strategy Officer Ghislain Gackière presents at the Neurotech Leaders
Something wrong or missing? Send an update. Fixed within 24 hours.